SF1670 |
| رقم الكتالوجGC10019 |
SF1670 هو متجانسة قوية ومحددة من الفوسفاتيز والتنسن تم حذفها على مثبط الكروموسوم 10 (PTEN)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 345630-40-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SF1670 is a potent and specific PTEN (phosphatase and tensin homolog deleted on chromosome 10) inhibitor[1]. SF1670 protects cells from oxygen-glucose deprivation-induced cell death[2]. SF1670 helps maintain the pluripotency of mouse embryonic stem cells (ESCs)[3].
In vitro, treatment of nucleus pulposus (NP) cells with SF1670 (0-5µM) for 3h significantly increased cell viability, inhibited PTEN expression, and activated Akt activity[4]. Pretreatment of neutrophils with SF1670 (125-500nM) for 30min dose-dependently enhanced fMLP-induced neutrophil polarization[5]. Treatment of MCF-7 cells with SF1670 (200nM) for 48h significantly inhibited curcumin-induced cell apoptosis and significantly upregulated p-AKT protein expression[6].
In vivo, SF1670 (3mg/kg) was intraperitoneally injected into mice with cerebral ischemia-reperfusion (I/R) injury, which attenuated the increase in thiobarbituric acid reactive substances (TBARS) induced by I/R and reversed the decrease in GSH levels and SOD activity[7].
References:
[1] Li F Q, Chen W B, Luo Z W, et al. Bone marrow mesenchymal stem cell-derived exosomal microRNAs target PI3K/Akt signaling pathway to promote the activation of fibroblasts[J]. World Journal of Stem Cells, 2023, 15(4): 248.
[2] Farajdokht F, Mohaddes G, Karimi-Sales E, et al. Inhibition of PTEN protects PC12 cells against oxygen-glucose deprivation induced cell death through mitoprotection[J]. Brain research, 2018, 1692: 100-109.
[3] Wang W, Lu G, Su X, et al. Pten-mediated Gsk3β modulates the naïve pluripotency maintenance in embryonic stem cells[J]. Cell Death & Disease, 2020, 11(2): 107.
[4] Fu H Y, Shen L, Gao X S, et al. SF1670 inhibits apoptosis and inflammation via the PTEN/Akt pathway and thus protects intervertebral disc degeneration[J]. European Review for Medical & Pharmacological Sciences, 2020, 24(17).
[5] Li Y, Prasad A, Jia Y, et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model[J]. Blood, The Journal of the American Society of Hematology, 2011, 117(24): 6702-6713.
[6] Li M Z, Wang C R, Lin C L. Curcumin promotes apoptosis of breast cancer cells by down-regulating DJ-1-PTEN/PI3K/AKT signaling pathways[J]. Int. J. Clin. Exp. Med, 2019, 12: 8992-8998.
[7] Grewal A K, Singh N, Singh T G. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia–reperfusion-induced injury in mice[J]. Journal of Pharmacy and Pharmacology, 2019, 71(6): 956-970.
| Cell experiment [1]: | |
Cell lines | Nucleus pulposus (NP) cells |
Preparation Method | NP cells were treated with 0, 0.5, 1, 2, and 5μM SF1670 for 3h, and then cell viability was measured using the CCK-8 assay. |
Reaction Conditions | 0, 0.5, 1, 2, and 5µM; 3h |
Applications | SF1670 treatment can improve the viability of NP cells, and the cell viability reached the highest level when treated with 2μM concentration. |
| Animal experiment [2]: | |
Animal models | Swiss albino male mice |
Preparation Method | Six male mice in each group were randomly selected and divided into nine groups. All the animals were subjected to behavioral tests and biochemical estimations during the study. Group I was a sham surgery group, and group II was I/R control group. For the reperfusion intervention (i.e. pPoCo), pharmacological agents CGS21680 (0.5mg/kg; i.p.) (in group V, VI, IX) and SF1670 (3mg/kg; i.p.) (in group VII, VIII, IX) were administered 5min before reper fusion of 24h so that the drug would be in circulation at the time of onset of reperfusion. |
Dosage form | 3mg/kg; i. p. |
Applications | SF1670 treatment attenuated the I/R-induced increase in thiobarbituric acid reactive substances (TBARS), and reversed the decrease in GSH levels and SOD activity. |
References: | |
| Cas No. | 345630-40-2 | SDF | |
| Chemical Name | N-(9,10-dioxo-9,10-dihydrophenanthren-2-yl)pivalamide | ||
| Canonical SMILES | CC(C)(C(NC(C=C1C2=O)=CC=C1C3=C(C2=O)C=CC=C3)=O)C | ||
| Formula | C19H17NO3 | M.Wt | 307.34 |
| الذوبان | ≥ 15.37mg/mL in DMSO | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2537 mL | 16.2686 mL | 32.5373 mL |
| 5 mM | 0.6507 mL | 3.2537 mL | 6.5075 mL |
| 10 mM | 0.3254 mL | 1.6269 mL | 3.2537 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *